药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Androstenediol
Larotrectinib
The serum concentration of Larotrectinib can be increased when it is combined with Laniquidar.
Androstenediol
Ivosidenib
The serum concentration of Ivosidenib can be increased when it is combined with Laniquidar.
Androstenediol
Tenofovir
The serum concentration of Tenofovir can be increased when it is combined with Laniquidar.
Androstenediol
Glecaprevir
The serum concentration of Glecaprevir can be increased when it is combined with Laniquidar.
Androstenediol
Pibrentasvir
The serum concentration of Pibrentasvir can be increased when it is combined with Laniquidar.
Androstenediol
Lusutrombopag
The serum concentration of Lusutrombopag can be increased when it is combined with Laniquidar.
Androstenediol
Grapiprant
The serum concentration of Grapiprant can be increased when it is combined with Laniquidar.
Androstenediol
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Laniquidar.
Clonitazene
Lefamulin
Lefamulin may increase the QTc-prolonging activities of Pilsicainide.
Clonitazene
Belantamab mafodotin
Pilsicainide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Clonitazene
Glycyrrhizic acid
Pilsicainide may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.
Clonitazene
Dihydroergocristine
Pilsicainide may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Clonitazene
Inotersen
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Inotersen.
Clonitazene
Aripiprazole lauroxil
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Aripiprazole lauroxil.
Clonitazene
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Pipemidic acid.
Clonitazene
Rufloxacin
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Rufloxacin.
Clonitazene
Piromidic acid
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Piromidic acid.
Clonitazene
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Oxolinic acid.
Clonitazene
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Pilsicainide.
Clonitazene
Triclabendazole
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Pilsicainide.